Netherlands: These 6 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

Generic name: ixazomib citrate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 06, 2027
Generic Entry Controlled by: Netherlands Patent 300,871

NINLARO is a drug marketed by Takeda Pharms Usa. There are seven patents protecting this drug.

This drug has one hundred and eighty-seven patent family members in forty-four countries. There has been litigation on patents covering NINLARO

See drug price trends for NINLARO.

The generic ingredient in NINLARO is ixazomib citrate. One supplier is listed for this generic product. Additional details are available on the ixazomib citrate profile page.

Generic name: empagliflozin; linagliptin
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 16, 2027
Generic Entry Controlled by: Netherlands Patent 300,872

GLYXAMBI is a drug marketed by Boehringer Ingelheim. There are fifteen patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has five hundred and twenty-one patent family members in forty-five countries. There has been litigation on patents covering GLYXAMBI

See drug price trends for GLYXAMBI.

The generic ingredient in GLYXAMBI is empagliflozin; linagliptin. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; linagliptin profile page.

Generic name: empagliflozin
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 16, 2027
Generic Entry Controlled by: Netherlands Patent 300,872

JARDIANCE is a drug marketed by Boehringer Ingelheim. There are fifteen patents protecting this drug and one Paragraph IV challenge. Eighteen tentatively approved generics are ready to enter the market.

This drug has four hundred and eighteen patent family members in forty-six countries. There has been litigation on patents covering JARDIANCE

See drug price trends for JARDIANCE.

The generic ingredient in JARDIANCE is empagliflozin. There are twenty-two drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the empagliflozin profile page.

Generic name: lefamulin acetate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 20, 2027
Generic Entry Controlled by: Netherlands Patent 301,086

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug.

This drug has one hundred and twenty patent family members in thirty-six countries. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

Generic name: telotristat etiprate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 12, 2026
Generic Entry Controlled by: Netherlands Patent 300,929

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

This drug has seventy patent family members in twenty-nine countries.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. One supplier is listed for this generic product. Additional details are available on the telotristat etiprate profile page.

Generic name: tepotinib hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: Netherlands Patent 301,176

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug.

This drug has seventy-nine patent family members in thirty-six countries. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the tepotinib hydrochloride profile page.

Generic name: finerenone
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 27, 2027
Generic Entry Controlled by: Netherlands Patent 301,192

KERENDIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug.

This drug has ninety-seven patent family members in forty-nine countries. There has been litigation on patents covering KERENDIA

See drug price trends for KERENDIA.

The generic ingredient in KERENDIA is finerenone. One supplier is listed for this generic product. Additional details are available on the finerenone profile page.

Generic name: difelikefalin acetate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 10, 2026
Generic Entry Controlled by: Netherlands Patent 301,199

KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.

This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA

See drug price trends for KORSUVA.

The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.

Generic name: cedazuridine; decitabine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 16, 2027
Generic Entry Controlled by: Netherlands Patent 301,256

INQOVI is a drug marketed by Taiho Oncology. There are six patents protecting this drug.

This drug has ninety-three patent family members in forty-one countries. There has been litigation on patents covering INQOVI

See drug price trends for INQOVI.

The generic ingredient in INQOVI is cedazuridine; decitabine. One supplier is listed for this generic product. Additional details are available on the cedazuridine; decitabine profile page.

Generic name: macitentan
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 29, 2026
Generic Entry Controlled by: Netherlands Patent 301,308

OPSUMIT is a drug marketed by Actelion. There are five patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred patent family members in thirty-five countries. There has been litigation on patents covering OPSUMIT

See drug price trends for OPSUMIT.

The generic ingredient in OPSUMIT is macitentan. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the macitentan profile page.

Generic name: macitentan; tadalafil
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 29, 2026
Generic Entry Controlled by: Netherlands Patent 301,308

OPSYNVI is a drug marketed by Actelion. There are three patents protecting this drug.

This drug has one hundred patent family members in thirty-five countries. There has been litigation on patents covering OPSYNVI

See drug price trends for OPSYNVI.

The generic ingredient in OPSYNVI is macitentan; tadalafil. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the macitentan; tadalafil profile page.

Generic name: cedazuridine; decitabine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 16, 2027
Generic Entry Controlled by: Netherlands Patent 301,257

INQOVI is a drug marketed by Taiho Oncology. There are six patents protecting this drug.

This drug has ninety-three patent family members in forty-one countries. There has been litigation on patents covering INQOVI

See drug price trends for INQOVI.

The generic ingredient in INQOVI is cedazuridine; decitabine. One supplier is listed for this generic product. Additional details are available on the cedazuridine; decitabine profile page.